Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Chinese Adolescents With Obesity
NCT07559136Phase 1Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS9531 in obesity (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Adverse Events. Started Jun 2026; status: active, not recruiting.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07559136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559136.